IL216365A - Use of 3'- [(z2) - [1- (4,3-dimethylphenyl) - 5,1- dihydro-3-methyl-5-oxo-4h- pyrazole-4-ylidene] hydrazano] - 2 '- Hydroxy - [1,1'-biphenyl] -3 - Carboxylic acid or its salt of pharmacy, for the preparation of drugs to treat thrombocytopenia - Google Patents

Use of 3'- [(z2) - [1- (4,3-dimethylphenyl) - 5,1- dihydro-3-methyl-5-oxo-4h- pyrazole-4-ylidene] hydrazano] - 2 '- Hydroxy - [1,1'-biphenyl] -3 - Carboxylic acid or its salt of pharmacy, for the preparation of drugs to treat thrombocytopenia

Info

Publication number
IL216365A
IL216365A IL216365A IL21636511A IL216365A IL 216365 A IL216365 A IL 216365A IL 216365 A IL216365 A IL 216365A IL 21636511 A IL21636511 A IL 21636511A IL 216365 A IL216365 A IL 216365A
Authority
IL
Israel
Prior art keywords
hydrazino
ylidene
pyrazol
dimethylphenyl
medicaments
Prior art date
Application number
IL216365A
Other languages
English (en)
Hebrew (he)
Other versions
IL216365A0 (en
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43223061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL216365(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of IL216365A0 publication Critical patent/IL216365A0/en
Publication of IL216365A publication Critical patent/IL216365A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL216365A 2009-05-29 2011-11-14 Use of 3'- [(z2) - [1- (4,3-dimethylphenyl) - 5,1- dihydro-3-methyl-5-oxo-4h- pyrazole-4-ylidene] hydrazano] - 2 '- Hydroxy - [1,1'-biphenyl] -3 - Carboxylic acid or its salt of pharmacy, for the preparation of drugs to treat thrombocytopenia IL216365A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18214809P 2009-05-29 2009-05-29
PCT/US2010/036294 WO2010138656A1 (en) 2009-05-29 2010-05-27 Methods of administration of thrombopoietin agonist compounds

Publications (2)

Publication Number Publication Date
IL216365A0 IL216365A0 (en) 2012-01-31
IL216365A true IL216365A (en) 2015-09-24

Family

ID=43223061

Family Applications (1)

Application Number Title Priority Date Filing Date
IL216365A IL216365A (en) 2009-05-29 2011-11-14 Use of 3'- [(z2) - [1- (4,3-dimethylphenyl) - 5,1- dihydro-3-methyl-5-oxo-4h- pyrazole-4-ylidene] hydrazano] - 2 '- Hydroxy - [1,1'-biphenyl] -3 - Carboxylic acid or its salt of pharmacy, for the preparation of drugs to treat thrombocytopenia

Country Status (20)

Country Link
US (1) US8609693B2 (enExample)
EP (2) EP2434894B1 (enExample)
JP (3) JP2012528184A (enExample)
KR (1) KR20120015355A (enExample)
CN (2) CN104173337A (enExample)
AU (1) AU2010254046C1 (enExample)
BR (1) BRPI1014548A2 (enExample)
CA (1) CA2763768A1 (enExample)
DK (1) DK3127427T3 (enExample)
EA (2) EA201690401A1 (enExample)
ES (2) ES2782898T3 (enExample)
HU (1) HUE049075T2 (enExample)
IL (1) IL216365A (enExample)
MX (1) MX2011012668A (enExample)
PL (2) PL3127427T3 (enExample)
PT (2) PT2434894T (enExample)
SG (1) SG176088A1 (enExample)
SI (1) SI3127427T1 (enExample)
WO (1) WO2010138656A1 (enExample)
ZA (1) ZA201108374B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045310A1 (en) * 2008-10-16 2010-04-22 Glaxosmithkline Llc Method of treating thrombocytopenia
PT2434894T (pt) 2009-05-29 2016-11-29 Novartis Ag Métodos de administração de compostos agonistas de trombopoietina

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE193350C (enExample)
US851444A (en) 1905-11-13 1907-04-23 Agfa Ag Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en) 1953-02-27 1957-07-24 Ciba Ltd Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
US2809963A (en) 1954-10-26 1957-10-15 Ciba Ltd Azo-dyestuffs
DE1046220B (de) 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
GB826207A (en) 1956-07-23 1959-12-31 Bayer Ag ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en) 1956-11-20 1960-08-23 Agfa Ag Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en) 1965-04-09 1968-01-30 Interchem Corp Disazo pyrazolone pigments
US4435417A (en) 1981-02-20 1984-03-06 Gruppo Lepetit S.P.A. Antiinflammatory 3H-naphtho[1,2-d]imidazoles
ES523609A0 (es) 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
FR2559483B1 (fr) 1984-02-10 1986-12-05 Sandoz Sa Composes heterocycliques contenant des groupes basiques et/ou cationiques, leur preparation et leur utilisation comme colorants
US4582831A (en) 1984-11-16 1986-04-15 Pfizer Inc. Anti-inflammatory polymorphic monoethanolamine salt of N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound, composition, and method of use therefor
FI91869C (fi) 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4880788A (en) 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (de) 1993-08-13 1995-02-15 Ciba-Geigy Ag Pigmentsalze
EP0661170B1 (en) 1993-12-28 1998-09-02 Dai Nippon Printing Co., Ltd. Thermal transfer sheet
US5482546A (en) 1994-03-30 1996-01-09 Canon Kabushiki Kaisha Dye, ink containing the same, and ink-jet recording method and instrument using the ink
TW496870B (en) 1994-03-31 2002-08-01 Amgen Inc Compositions methods for stimulating megakaryocyte growth and differentiation
US5760038A (en) 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en) 1995-02-13 1998-05-05 Engelhard Corporation Pigment compositions
PT885242E (pt) 1995-06-07 2008-06-18 Glaxo Group Ltd Péptidos e compostos que se ligam a um receptor de trombopoietina
US5622818A (en) 1995-11-29 1997-04-22 Eastman Kodak Company Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en) 1996-05-30 1997-09-23 Engelhard Corporation Pigment compositions
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
GB9715830D0 (en) 1997-07-25 1997-10-01 Basf Ag Reactive dyes containing piperazine
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
CA2308317A1 (en) 1997-10-31 1999-05-14 Smithkline Beecham Corporation Novel metal complexes
DE19851389A1 (de) 1998-11-07 2000-05-11 Dystar Textilfarben Gmbh & Co Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
CO5210907A1 (es) 1999-05-12 2002-10-30 Novartis Ag Solvatos de pometrozina, insecticidamente activos, composiciones que contienen estos compuestos y metodos tanto para producir dichos compuestos y composiciones como para controlar plagas animales con estas composiciones
KR20020069183A (ko) 1999-07-26 2002-08-29 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 작동성을 나타내는 의약 조성물
WO2001017349A1 (en) 1999-09-10 2001-03-15 Smithkline Beckman Corporation Thrombopoietin mimetics
DE60032783T2 (de) 1999-09-24 2007-12-06 Smithkline Beecham Corp. Thrombopoietinmimetika
AU1462201A (en) 1999-11-05 2001-06-06 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
ES2160560T1 (es) 1999-11-10 2001-11-16 Curacyte Ag Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias.
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US6436915B1 (en) 2000-04-07 2002-08-20 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
HUP0001417A2 (hu) 2000-04-07 2002-12-28 Sanofi-Synthelabo Gyógyászatilag alkalmazható új sók, eljárás előállításukra és azokat tartalmazó gyógyászati készítmények
US6214813B1 (en) 2000-04-07 2001-04-10 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
WO2002049413A2 (en) 2000-12-19 2002-06-27 Smithkline Beecham Corporation Thrombopoietin mimetics
DE60132488D1 (de) 2000-12-21 2008-03-06 Ligand Pharmaceuticals Regulierte aktivierung von zellmembranrezeptoren durch metallchelatisierende agonisten
WO2002059099A1 (en) 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Cyclic compounds having thrombopoietin receptor agonism
CA2435143A1 (en) 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Halogen compounds having thrombopoietin receptor agonism
EP1370252A4 (en) 2001-03-01 2006-04-05 Smithkline Beecham Corp Thrombopoietin mimetics
JP3927001B2 (ja) 2001-06-15 2007-06-06 三菱化学株式会社 色素セット、インクセット並びに記録方法
CN1671379A (zh) 2001-11-30 2005-09-21 Qlt公司 亚肼基吡唑衍生物和它们作为治疗剂的用途
WO2003074550A2 (en) 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
TWI280128B (en) 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
AU2003248630A1 (en) 2002-06-06 2003-12-22 Smithkline Beecham Corporation Thrombopoietin mimetics
JP4317818B2 (ja) 2002-09-30 2009-08-19 アステラス製薬株式会社 ２−アシルアミノチアゾール誘導体の新規な塩
WO2004054515A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Thrombopoietin mimetics
JP4895807B2 (ja) 2003-04-29 2012-03-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 変性疾患／損傷の治療方法
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
JP2009508476A (ja) * 2005-08-31 2009-03-05 セントカー・インコーポレーテツド 高められたエフェクター機能をもつ抗体定常領域の製造用の宿主細胞株
US20070202140A1 (en) * 2005-12-22 2007-08-30 Veltri Enrico P Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
US20090304634A1 (en) 2006-12-12 2009-12-10 Smithkline Beecham Corporation Novel Combinations
UY30915A1 (es) 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
WO2009151862A1 (en) 2008-05-15 2009-12-17 Smithkline Beecham Corporation Method of treatment
WO2010045310A1 (en) 2008-10-16 2010-04-22 Glaxosmithkline Llc Method of treating thrombocytopenia
EP2427053A4 (en) 2009-05-07 2012-12-05 Glaxosmithkline Llc METHOD FOR TREATING THROMBOCYTOPENIA
PT2434894T (pt) 2009-05-29 2016-11-29 Novartis Ag Métodos de administração de compostos agonistas de trombopoietina
CN111399357A (zh) 2015-04-11 2020-07-10 安田斯研究所有限公司 影像识别方法及记录媒介

Also Published As

Publication number Publication date
CN102458120A (zh) 2012-05-16
SI3127427T1 (sl) 2020-07-31
CN104173337A (zh) 2014-12-03
AU2010254046B2 (en) 2013-10-10
PT3127427T (pt) 2020-04-17
SG176088A1 (en) 2011-12-29
IL216365A0 (en) 2012-01-31
ES2605593T3 (es) 2017-03-15
JP2016020360A (ja) 2016-02-04
EP2434894B1 (en) 2016-08-31
EP3127427B1 (en) 2020-01-08
WO2010138656A1 (en) 2010-12-02
JP2012528184A (ja) 2012-11-12
MX2011012668A (es) 2011-12-16
US20120064036A1 (en) 2012-03-15
EP2434894A4 (en) 2013-02-20
EP3127427A1 (en) 2017-02-08
EP2434894A1 (en) 2012-04-04
ZA201108374B (en) 2012-07-25
US8609693B2 (en) 2013-12-17
EA201171462A1 (ru) 2012-05-30
DK3127427T3 (da) 2020-04-06
ES2782898T3 (es) 2020-09-16
BRPI1014548A2 (pt) 2015-08-25
KR20120015355A (ko) 2012-02-21
AU2010254046C1 (en) 2014-03-06
JP2017226668A (ja) 2017-12-28
PL3127427T3 (pl) 2020-06-15
AU2010254046A1 (en) 2011-12-08
PT2434894T (pt) 2016-11-29
EA201690401A1 (ru) 2016-06-30
EA024557B1 (ru) 2016-09-30
HUE049075T2 (hu) 2020-08-28
PL2434894T3 (pl) 2017-04-28
CA2763768A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
IL250439A0 (en) Use of fingolimod, or a phosphate derivative thereof or a pharmaceutical acceptable salt thereof for the preparation of a drug for the treatment of multiple sclerosis
WO2012047017A3 (ko) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
UA115320C2 (uk) Інгібітори кінази
IL184148A (en) History of triazole is claimed as oxytocin antagonists, their pharmacological preparations and their use in the preparation of drugs for the treatment of disorders in which the inhibition of oxytocin gives a beneficial effect
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
GB0722077D0 (en) Compounds
AP2010005508A0 (en) Triazole derivatives useful for the treatment of diseases.
IL203051A (en) Use of alpha-ketoglutarate for drug preparation
IL212568A (en) Annotated 4,1-Diazepan, Pharmaceutical Preparations Containing Them and Their Uses in the Preparation of Medicines for the Treatment of Diseases or Disorders of Mammals
WO2008035359A3 (en) Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
PH12012502216A1 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienyl-methylbenzene derivatives as inhibitors of sglt
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
SG175066A1 (en) 6'-sialyllactose salts and process for their synthesis and for the synthesis of other a-sialyloligosaccharides
PL2196206T3 (pl) Środek do łagodzenia problemów skórnych zawierający pochodną morfinanu lub jego farmakologicznie dopuszczalną kwasową sól addycyjną jako substancję czynną
IL214133A (en) Isolated or cleaned Inganol or its pharmacist salt for skin care
NZ596820A (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
IL217300A0 (en) Pyrazole derivatives' prepartion thereof, and therapeutic use thereof
ZA200902451B (en) Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments
WO2008074833A3 (en) Compounds
WO2009003719A3 (en) Indane-amine derivatives, their preparation and use as medicaments
IL201562A0 (en) Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
MX2010001705A (es) Co-cristales de pirimetanilo y ditianona.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees